SCHEMBL2865259

SCHEMBL2865259

CN1CCC(NC(=O)C2CNCC3C(=O)OC(c4ccccc4)(c4ccccc4)N23)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 1/20 0.40
NPSR1 Q6W5P4 1/20 0.38
SSTR4 P31391 4/20 0.36
CHRM2 P08172 1/20 0.34
CHRM3 P20309 1/20 0.34
DYRK1A Q13627 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPK1 P28482 2/20 0.33
DCLK1 O15075 1/20 0.33
PDPK1 O15530 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33
CHEK2 O96017 1/20 0.33
PIM1 P11309 1/20 0.33
AXL P30530 1/20 0.33
FLT4 P35916 1/20 0.33
FLT3 P36888 1/20 0.33
MAPK9 P45984 1/20 0.33
CSNK1D P48730 1/20 0.33
IRAK1 P51617 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2861560 0.90 CCR1 (0.42) NPSR1ALDH1A1CCR1MC4R
SCHEMBL6039452 0.89 HTR4 (0.39) NPSR1CHRM2CHRM3ALDH1A1MAPK1
Hydrochloric Acid SCHEMBL2862020 0.88 HTR4 (0.39) NPSR1CHRM2CHRM3ALDH1A1MAPK1
SCHEMBL2868957 0.86 EPHX2 (0.41) NPSR1MAPK1FPR3FPR2
SCHEMBL2862082 0.83 HTR4 (0.43) NPSR1
SCHEMBL2861714 0.81 NPSR1 (0.40) NPSR1SSTR4MC4R
SCHEMBL2865537 0.81 ALDH1A1 (0.40) ALDH1A1
Hydrochloric Acid SCHEMBL2863761 0.80 NPSR1 (0.40) NPSR1CHRM2CHRM3ALDH1A1MC4R
SCHEMBL2870925 0.80 NPSR1 (0.36) NPSR1
SCHEMBL2860998 0.79 NPSR1 (0.41) NPSR1SSTR4MC4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 P2RX4 1524/4885NPSR1 211/4885SSTR4 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.